400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Cell Cycle / HSP / Elesclomol/伊利司莫
CAS No.: 488832-69-5
Synonyms: STA-4783;伊利司莫
Elesclomol, an inhibitor of HSP90, is a potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00088088 | Stage IIIB Non-Small Cell Lung... more >> Cancer Stage IV Non-Small Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Completed | - | United States, Arkansas ... more >> NEA Clinic Jonesboro, Arkansas, United States, 72401 United States, California Wilshire Oncology Medical Group Pamona, California, United States, 91767 St. Francis Memorial Hospital San Francisco, California, United States Cancer Institute Medical Group Santa Monica, California, United States, 90404 Kaiser Permanete Vallejo, California, United States United States, Connecticut Oncology Associates of Bridgeport Trumball, Connecticut, United States, 06611 United States, Florida ACORN Miami, Florida, United States Oncology Hematology Consultants Sarasota, Florida, United States, 34236 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 The Cancer Institute at Alexian Brothers Elk Grove Village, Illinois, United States, 60007 Ingalls Hospital Harvey, Illinois, United States, 60426 United States, Louisiana Overton Brooks, VAMC Shreveport, Louisiana, United States, 71101 LSUHSC - Shreveport Feist Weiller Cancer Center Shreveport, Louisiana, United States, 71130 United States, Maryland Maryland Hematology and Oncology Associates Baltimore, Maryland, United States, 21236 United States, Minnesota The Duluth Clinic Duluth, Minnesota, United States, 55805 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 The Sarah Cannon Research Center Nashville, Tennessee, United States, 37203 United States, Texas Presbyterian Hospital Dallas, Texas, United States, 75231 United States, Washington Multicare Health System Tacoma, Washington, United States, 98405 Collapse << |
NCT00087997 | Soft Tissue Sarcoma | Phase 2 | Completed | - | - |
NCT00522834 | Melanoma | Phase 3 | Terminated | - | - |
实验方案
技术信息
CAS号 | 488832-69-5 | 储存条件 |
|
|||||||||||
分子式 | C19H20N4O2S2 | 运输 | 蓝冰 | |||||||||||
分子量 | 400.52 | 别名 | STA-4783;伊利司莫 | |||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
647-V cell | - | Growth inhibition assay | - | Inhibition of human 647-V cell growth in a cell viability assay, IC50=6.9 nM | SANGER |
697 cell | - | Growth inhibition assay | - | Inhibition of human 697 cell growth in a cell viability assay, IC50=6.13 nM | SANGER |
A2780 cell | - | Growth inhibition assay | - | Inhibition of human A2780 cell growth in a cell viability assay, IC50=0.594 nM | SANGER |
A375 cell | - | Growth inhibition assay | - | Inhibition of human A375 cell growth in a cell viability assay, IC50=4.14 nM | SANGER |
A427 cell | - | Growth inhibition assay | - | Inhibition of human A427 cell growth in a cell viability assay, IC50=6.07 nM | SANGER |
A549 cell | - | Growth inhibition assay | - | Inhibition of human A549 cell growth in a cell viability assay, IC50=19.6 nM | SANGER |
A673 cell | - | Growth inhibition assay | - | Inhibition of human A673 cell growth in a cell viability assay, IC50=11.6 nM | SANGER |
A704 cell | - | Growth inhibition assay | - | Inhibition of human A704 cell growth in a cell viability assay, IC50=27.45 nM | SANGER |
ABC-1 cell | - | Growth inhibition assay | - | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50=0.365 nM | SANGER |
AGS cell | - | Growth inhibition assay | - | Inhibition of human AGS cell growth in a cell viability assay, IC50=2.86 nM | SANGER |
BCPAP cell | - | Growth inhibition assay | - | Inhibition of human BCPAP cell growth in a cell viability assay, IC50=1.34 nM | SANGER |
BHT-101 cell | - | Growth inhibition assay | - | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50=3.72 nM | SANGER |
BV-173 cell | - | Growth inhibition assay | - | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=5.39 nM | SANGER |
C-33-A cell | - | Growth inhibition assay | - | Inhibition of human C-33-A cell growth in a cell viability assay, IC50=7.58 nM | SANGER |
Ca9-22 cell | - | Growth inhibition assay | - | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50=4.25 nM | SANGER |
CAL-51 cell | - | Growth inhibition assay | - | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=0.126 nM | SANGER |
CAL-72 cell | - | Growth inhibition assay | - | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=3.02 nM | SANGER |
CHL-1 cell | - | Growth inhibition assay | - | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50=2.81 nM | SANGER |
CHP-212 cell | - | Growth inhibition assay | - | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=7.34 nM | SANGER |
COLO-684 cell | - | Growth inhibition assay | - | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=9.21 nM | SANGER |
COR-L105 cell | - | Growth inhibition assay | - | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50=6.76 nM | SANGER |
DMS-273 cell | - | Growth inhibition assay | - | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=7.06 nM | SANGER |
ES1 cell | - | Growth inhibition assay | - | Inhibition of human ES1 cell growth in a cell viability assay, IC50=0.749 nM | SANGER |
ES3 cell | - | Growth inhibition assay | - | Inhibition of human ES3 cell growth in a cell viability assay, IC50=5.79 nM | SANGER |
ES4 cell | - | Growth inhibition assay | - | Inhibition of human ES4 cell growth in a cell viability assay, IC50=4.39 nM | SANGER |
ES7 cell | - | Growth inhibition assay | - | Inhibition of human ES7 cell growth in a cell viability assay, IC50=3.59 nM | SANGER |
ES8 cell | - | Growth inhibition assay | - | Inhibition of human ES8 cell growth in a cell viability assay, IC50=1.32 nM | SANGER |
EW-1 cell | - | Growth inhibition assay | - | Inhibition of human EW-1 cell growth in a cell viability assay, IC50=5.24 nM | SANGER |
EW-11 cell | - | Growth inhibition assay | - | Inhibition of human EW-11 cell growth in a cell viability assay, IC50=4.9 nM | SANGER |
EW-16 cell | - | Growth inhibition assay | - | Inhibition of human EW-16 cell growth in a cell viability assay, IC50=1.61 nM | SANGER |
EW-24 cell | - | Growth inhibition assay | - | Inhibition of human EW-24 cell growth in a cell viability assay, IC50=3.83 nM | SANGER |
F-36P cells | - | Proliferation assay | - | Antiproliferative activity against human F-36P cells, IC50=0.28 μM | 21341675 |
FADU cell | - | Growth inhibition assay | - | Inhibition of human FADU cell growth in a cell viability assay, IC50=5.66 nM | SANGER |
G-401 cell | - | Growth inhibition assay | - | Inhibition of human G-401 cell growth in a cell viability assay, IC50=5.43 nM | SANGER |
GAMG cell | - | Growth inhibition assay | - | Inhibition of human GAMG cell growth in a cell viability assay, IC50=2.51 nM | SANGER |
GB-1 cell | - | Growth inhibition assay | - | Inhibition of human GB-1 cell growth in a cell viability assay, IC50=6.71 nM | SANGER |
HCE-T cell | - | Growth inhibition assay | - | Inhibition of human HCE-T cell growth in a cell viability assay, IC50=4.45 nM | SANGER |
HD-MY-Z cell | - | Growth inhibition assay | - | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=5.91 nM | SANGER |
HEL cell | - | Growth inhibition assay | - | Inhibition of human HEL cell growth in a cell viability assay, IC50=7.08 nM | SANGER |
H-EMC-SS cell | - | Growth inhibition assay | - | Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50=3.68 nM | SANGER |
HOS cell | - | Growth inhibition assay | - | Inhibition of human HOS cell growth in a cell viability assay, IC50=2.53 nM | SANGER |
HSC-3 cell | - | Growth inhibition assay | - | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50=3.02 nM | SANGER |
HSC-4 cell | - | Growth inhibition assay | - | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50=4.8 nM | SANGER |
HT-1080 cell | - | Growth inhibition assay | - | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=4.99 nM | SANGER |
HuCCT1 cell | - | Growth inhibition assay | - | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50=5.52 nM | SANGER |
human H4 cell | - | Growth inhibition assay | - | Inhibition of human H4 cell growth in a cell viability assay, IC50=7.25 nM | SANGER |
human JAR cell | - | Growth inhibition assay | - | Inhibition of human JAR cell growth in a cell viability assay, IC50=5.97 nM | SANGER |
human K5 cell | - | Growth inhibition assay | - | Inhibition of human K5 cell growth in a cell viability assay, IC50=7 nM | SANGER |
human KU-19-19 cell | - | Growth inhibition assay | - | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=7.09 nM | SANGER |
human NB14 cell | - | Growth inhibition assay | - | Inhibition of human NB14 cell growth in a cell viability assay, IC50=6.64 nM | SANGER |
human SW982 cell | - | Growth inhibition assay | - | Inhibition of human SW982 cell growth in a cell viability assay, IC50=7.44 nM | SANGER |
human T47D cell | - | Growth inhibition assay | - | Inhibition of human T47D cell growth in a cell viability assay, IC50=16.79 nM | SANGER |
HUTU-80 cell | - | Growth inhibition assay | - | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=0.791 nM | SANGER |
K562 cells | - | Proliferation assay | - | Antiproliferative activity against human K562 cells, IC50=18 μM | 21341675 |
KOSC-2 cell | - | Growth inhibition assay | - | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50=5.45 nM | SANGER |
KP-4 cell | - | Growth inhibition assay | - | Inhibition of human KP-4 cell growth in a cell viability assay, IC50=2.17 nM | SANGER |
MCF7 cell | - | Growth inhibition assay | - | Inhibition of human MCF7 cell growth in a cell viability assay, IC50=31.36 nM | SANGER |
MC-IXC cell | - | Growth inhibition assay | - | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=7.17 nM | SANGER |
MDA-MB-157 cell | - | Growth inhibition assay | - | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50=2.92 nM | SANGER |
MES-SA/Dx5 cells | - | Cytotoxicity assay | - | Cytotoxicity against human MES-SA/Dx5 cells, IC50=5 nM | 23937981 |
MHH-ES-1 cell | - | Growth inhibition assay | - | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50=5.69 nM | SANGER |
MOLT-16 cell | - | Growth inhibition assay | - | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=4.53 nM | SANGER |
NB69 cell | - | Growth inhibition assay | - | Inhibition of human NB69 cell growth in a cell viability assay, IC50=1.22 nM | SANGER |
NBsusSR cell | - | Growth inhibition assay | - | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=3.13 nM | SANGER |
NCI-H1563 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50=4.13 nM | SANGER |
NCI-H1703 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50=3.68 nM | SANGER |
NCI-H292 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=0.886 nM | SANGER |
NCI-SNU-1 cell | - | Growth inhibition assay | - | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50=4.86 nM | SANGER |
NOS-1 cell | - | Growth inhibition assay | - | Inhibition of human NOS-1 cell growth in a cell viability assay, 3.66e-05 μM | SANGER |
NUGC-3 cell | - | Growth inhibition assay | - | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50=7.33 nM | SANGER |
OCI-AML2 cells | - | Proliferation assay | - | Antiproliferative activity against human OCI-AML2 cells, IC50=0.35 μM | 21341675 |
OVCAR-3 cell | - | Growth inhibition assay | - | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=6.2 nM | SANGER |
OVCAR-4 cell | - | Growth inhibition assay | - | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=5.87 nM | SANGER |
OVCAR-5 cell | - | Growth inhibition assay | - | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50=1.83 nM | SANGER |
OVCAR-8 cell | - | Growth inhibition assay | - | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50=3.99 nM | SANGER |
PC-14 cell | - | Growth inhibition assay | - | Inhibition of human PC-14 cell growth in a cell viability assay, IC50=24.73 nM | SANGER |
PC-3 cell | - | Growth inhibition assay | - | Inhibition of human PC-3 cell growth in a cell viability assay, IC50=7.89 nM | SANGER |
PC3 cells | - | Function assay | - | Inhibition of PDK1-mediated AKT phosphorylation at Thr308 residue in human PC3 cells by ELISA, IC50=0.113 μM | 21341675 |
PSN1 cell | - | Growth inhibition assay | - | Inhibition of human PSN1 cell growth in a cell viability assay, IC50=3.84 nM | SANGER |
SF126 cell | - | Growth inhibition assay | - | Inhibition of human SF126 cell growth in a cell viability assay, IC50=1.95 nM | SANGER |
SK-OV-3 cell | - | Growth inhibition assay | - | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=3.75 nM | SANGER |
SNU-387 cell | - | Growth inhibition assay | - | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50=9.49 nM | SANGER |
SW1710 cell | - | Growth inhibition assay | - | Inhibition of human SW1710 cell growth in a cell viability assay, IC50=5.16 nM | SANGER |
SW1990 cell | - | Growth inhibition assay | - | Inhibition of human SW1990 cell growth in a cell viability assay, IC50=4.32 nM | SANGER |
SW756 cell | - | Growth inhibition assay | - | Inhibition of human SW756 cell growth in a cell viability assay, IC50=4.13 nM | SANGER |
T-24 cell | - | Growth inhibition assay | - | Inhibition of human T-24 cell growth in a cell viability assay, IC50=1.55 nM | SANGER |
TE-8 cell | - | Growth inhibition assay | - | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=5.41 nM | SANGER |
U251 cell | - | Growth inhibition assay | - | Inhibition of human U251 cell growth in a cell viability assay, IC50=9.86 nM | SANGER |
UM-UC-3 cell | - | Growth inhibition assay | - | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50=7.06 nM | SANGER |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00088088 | Stage IIIB Non-Small Cell Lung... more >> Cancer Stage IV Non-Small Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Completed | - | United States, Arkansas ... more >> NEA Clinic Jonesboro, Arkansas, United States, 72401 United States, California Wilshire Oncology Medical Group Pamona, California, United States, 91767 St. Francis Memorial Hospital San Francisco, California, United States Cancer Institute Medical Group Santa Monica, California, United States, 90404 Kaiser Permanete Vallejo, California, United States United States, Connecticut Oncology Associates of Bridgeport Trumball, Connecticut, United States, 06611 United States, Florida ACORN Miami, Florida, United States Oncology Hematology Consultants Sarasota, Florida, United States, 34236 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 The Cancer Institute at Alexian Brothers Elk Grove Village, Illinois, United States, 60007 Ingalls Hospital Harvey, Illinois, United States, 60426 United States, Louisiana Overton Brooks, VAMC Shreveport, Louisiana, United States, 71101 LSUHSC - Shreveport Feist Weiller Cancer Center Shreveport, Louisiana, United States, 71130 United States, Maryland Maryland Hematology and Oncology Associates Baltimore, Maryland, United States, 21236 United States, Minnesota The Duluth Clinic Duluth, Minnesota, United States, 55805 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 The Sarah Cannon Research Center Nashville, Tennessee, United States, 37203 United States, Texas Presbyterian Hospital Dallas, Texas, United States, 75231 United States, Washington Multicare Health System Tacoma, Washington, United States, 98405 Collapse << |
NCT00087997 | Soft Tissue Sarcoma | Phase 2 | Completed | - | - |
NCT00522834 | Melanoma | Phase 3 | Terminated | - | - |
NCT00088114 | Neoplasms | Phase 1 | Completed | - | United States, Massachusetts ... more >> Beth Israel-Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Collapse << |
NCT00827203 | Metastatic Solid Tumors | Phase 1 | Suspended | January 2011 | United States, Maryland ... more >> Mayo Clinic Rochester, Maryland, United States, 55905 United States, Texas University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 United States, Wisconsin University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Collapse << |
NCT00888615 | Fallopian Tube Clear Cell Aden... more >>ocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Tumor Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Undifferentiated Fallopian Tube Carcinoma Undifferentiated Ovarian Carcinoma Collapse << | Phase 2 | Active, not recruiting | - | - |
NCT00084214 | Melanoma | Phase 1 Phase 2 | Completed | - | - |
NCT01280786 | Acute Myeloid Leukemia | Phase 1 | Unknown | August 2014 | Canada, Ontario ... more >> Princess Margaret Hospital Toronto, Ontario, Canada, MSG 2M9 Collapse << |
NCT00808418 | Prostate Cancer | Phase 1 | Completed | - | United States, California ... more >> Pacific Coast Hematology/Oncology Medical Group Fountain Valley, California, United States, 92708 United States, Maryland Mayo Clinic Rochester, Maryland, United States, 55905 United States, North Dakota Mid Dakota Clinic Bismarck, North Dakota, United States, 58501 United States, Texas University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 United States, Wisconsin University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Collapse << |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网